This Poster presentation is under embargo until 23 March 2026, as per congress regulations.

Please subscribe using the button below to receive a notification when the material becomes available:

Register for email alerts

 

 

Publication
  • EBMT •
  • 23 March, 2026 •
  • •

Emapalumab is associated with Rapid and Sustained Benefits in pHLH Subgroups, Including CNS Involvement and Previously Untreated Patients: Analysis of trials NI-0501-04, NI-050105 and NI-050109

Franco Locatelli, Michael B. Jordan, Didier Halimi, Elena Burillo, Brian D. Jamieson, Emmanuel Monnet, Andrew Danquah

Publication
  • ASH •
  • 8 December, 2025 •
  • •

Emapalumab induces rapid, durable responses and reliable bridging to curative HSCT in patients with primary HLH: Pooled analysis of prospective trials NI-0501-04, NI-0501-05 and NI-0501-09

Michael B. Jordan, Franco Locatelli, Didier Halimi, Elena Burillo, Brian D. Jamieson, Andrew Danquah, Emmanuel Monnet

Publication
  • ASH •
  • 7 December, 2025 •
  • •

Use of Emapalumab is associated with Rapid and Sustained Benefits in pHLH Subgroups, Including CNS Involvement and Previously Untreated Patients: Pooled analysis of prospective trials NI-0501-04, NI-050105 and NI-050109

Franco Locatelli, Michael B. Jordan, Didier Halimi, Elena Burillo, Brian D. Jamieson, Emmanuel Monnet, Andrew Danquah

Publication
  • EHA •
  • 12 June, 2025 •
  • •

Emapalumab in patients with primary hemophagocytic lymphohistiocytosis: Efficacy and safety outcomes from a multinational, open-label, single-arm study

Franco Locatelli, Ahmed Naqvi, Beki James, Julián Sevilla, Simone Cesaro, Stephan Ehl, Didier Halimi, Emmanuel Monnet, Ben Peace, Veronica Asnaghi, Cristina de Min, Michael Jordan

Available materials

Poster
Sign up for alerts